---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-023969"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:35:01.244047+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q1 revenue up 22% to $13.7M; GAAP net loss widens to $3.8M

## Summary
- Revenue $13.7M, +22% YoY; gross margin 59% vs 55%.
- GAAP net loss $3.8M ($0.21 per share) vs loss $0.6M ($0.04) in Q1 2021.
- Non-GAAP net loss $0.1M ($0.01 per share); cash $89.0M.
- Reaffirmed FY2022 revenue guidance $80-85M (31-39% growth) and gross margin 57-60%.
- Completed EvinceMed acquisition, a specialty drug prescription initiation platform.

## SEC filing metadata
- accession: 0001213900-22-023969
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390022023969/0001213900-22-023969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390022023969/ea159377-8k_optimizerx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-023969
- JSON: https://secwatch.observer/filing/0001213900-22-023969.json
- Plain text: https://secwatch.observer/filing/0001213900-22-023969.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.